Angle Plc - ANPCY STOCK NEWS

Welcome to our dedicated page for Angle Plc news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on Angle Plc stock.

ANGLE PLC S/ADR (ANPCY) is a world-leading liquid biopsy company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology. The company's proprietary Parsortix system efficiently harvests CTCs from blood samples, enabling downstream molecular analysis for comprehensive biomarker assessment. ANGLE's cutting-edge technologies, such as the Portrait+ CTC Staining Kit, enable the identification and analysis of diverse CTC phenotypes and clusters, providing valuable insights into cancer progression, metastasis, and treatment response. With a focus on diagnostic products and clinical services, ANGLE continues to drive advancements in precision medicine through its state-of-the-art liquid biopsy solutions.

05/16/2024 02:00 AM

News

Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix

Rhea-AI Summary

Angle PLC announced a study using their Parsortix system to analyze circulating tumor cells (CTCs) from 123 metastatic ovarian cancer patients over two and a half years. The study, the largest of its kind, involved 474 blood samples and identified two key gene markers: ERCC1, linked to worse outcomes, and ESR1, linked to better outcomes. The presence of ESR1 and absence of ERCC1 in CTCs correlated with improved progression-free survival (PFS). This research suggests that molecular characterization of CTCs could be valuable for monitoring ovarian cancer and predicting treatment responses in clinical trials.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.42%

Tags

05/03/2024 02:00 AM

News

Angle PLC Announces New Commercial Agreement with Large Pharma

Rhea-AI Summary

ANGLE plc has announced a new commercial agreement with AstraZeneca to develop a Parsortix-based Androgen Receptor detection assay for prostate cancer studies, worth £550,000. The assay is expected to be completed by Q1 2025 and could provide significant revenue opportunities for the company. The Parsortix system will allow for minimally invasive assessment of the Androgen Receptor status, important in prostate cancer treatment. This agreement further validates ANGLE's technology and potential for long-term revenue growth.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/24/2024 02:00 AM

News

Angle PLC Announces New Commercial Agreement with AstraZeneca

Rhea-AI Summary

ANGLE plc has signed a commercial agreement with AstraZeneca to develop a methodology using its DNA damage response assay for detecting micronuclei in circulating tumor cells. The agreement is worth £150,000 for a 6-month development phase. The DDR therapeutics market is projected to reach $10.4 billion by 2031 with a CAGR of 6.5%, driven by the need for novel targeted medicines for cancer treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/22/2024 02:00 AM

News

Angle PLC Announces US and EU Patents for Innovative CellKeep(TM) Slide

Rhea-AI Summary

ANGLE plc has secured US and EU patents for its CellKeep slide, reducing over 70% of CTC cell loss during microscopy, enhancing assay sensitivity. The innovative device improves CTC attachment to slides, increasing cell preservation and reducing costs. The technology significantly boosts identification rates of CTCs and biomarkers, advancing precision medicine for cancer patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/08/2024 02:00 AM

News

Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024

Rhea-AI Summary

ANGLE plc (ANPCY) presents Parsortix HER2 assay at AACR Annual Meeting 2024, showcasing a novel assay for HER2 assessment on circulating tumor cells. The assay, developed in collaboration with BioView, aims to evaluate HER2 gene amplification and protein expression in metastatic breast cancer patients. The presented data demonstrates successful identification of HER2 positive CTCs, potentially benefiting patients who may require HER2-targeted therapies. Liquid biopsy evaluation offers a minimally invasive technique for monitoring HER2 status over time, providing valuable data for treatment decisions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/22/2024 03:00 AM

News

Angle PLC Announces Parsortix at European Breast Cancer Conference

Rhea-AI Summary

ANGLE plc showcases Parsortix system and assays at a leading European Breast Cancer Conference. The company presents two posters highlighting the utility of its new Portrait+ CTC Staining Kit and Portrait HER2 assay. ANGLE's technology enables comprehensive analysis of circulating tumor cells, including mesenchymal CTCs and CTC clusters, crucial for cancer progression and metastasis. The company's IF assay for HER2 status in CTCs offers a minimally invasive alternative to tissue biopsies, allowing for dynamic monitoring and potential clinical decision-making in metastatic breast cancer patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/22/2024 02:00 AM

News

Angle PLC Announces Potential Utility in Precision Oncology

Rhea-AI Summary

ANGLE plc announces breakthrough data from a newly established workflow for real-time parallel Next Generation Sequencing (NGS) DNA analysis of both ctDNA and CTCs from a single tube of patient blood. The peer-reviewed paper in 'Current Issues in Molecular Biology' highlights the potential utility of Parsortix CTC harvest in precision oncology. The study showcases the benefits of utilizing the Parsortix system for downstream molecular analysis across various cancer types. The findings demonstrate the value of a dual analyte approach for both CTCs and ctDNA in informing prognosis, treatment selection, monitoring of treatment resistance, and disease relapse.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/10/2024 08:40 AM

News

Angle PLC Announces Standard Form for Notification of Major Holdings

Rhea-AI Summary

ANGLE plc (TR-1): Notification of Major Holdings by Global Frontier Investments, LLC and Global Frontier Partners, LP

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/02/2024 02:00 AM

News

Angle PLC - Contract announcement with Eisai Inc.

Rhea-AI Summary

ANGLE plc (AIM:AGL OTCQX:ANPCY) has signed a contract with Eisai Inc. for a pilot study worth US $250,000 to provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701, offering potential for multiple large-scale follow-up studies. The global HER2+ breast cancer ADC market is predicted to reach US $3.3 billion per annum by 2030, and ANGLE's Portrait HER2 assay enables accurate stratification of patient populations throughout the treatment pathway. The company's CEO, Andrew Newland, highlighted the potential of the study for major expansion of this line of business going forward.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/11/2023 02:00 AM

News

Angle PLC Announces Broker Announcement

Rhea-AI Summary

ANGLE plc (AGL) announces Berenberg as Nominated Adviser and Sole Broker. The company, a leader in liquid biopsy and CTC diagnostic solutions, will benefit from Berenberg's expertise in this strategic partnership.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of Angle Plc (ANPCY)?

The current stock price of Angle Plc (ANPCY) is $1.8465 as of February 7, 2025.

What is the market cap of Angle Plc (ANPCY)?

The market cap of Angle Plc (ANPCY) is approximately 62.9M.

What is ANGLE PLC S/ADR known for?

ANGLE is a world-leading liquid biopsy company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology.

What technologies does ANGLE use for CTC analysis?

ANGLE utilizes the Parsortix system for efficient harvesting of CTCs from blood samples, enabling downstream molecular analysis for comprehensive biomarker assessment.

How does ANGLE's Portrait+ CTC Staining Kit benefit cancer research?

The Portrait+ CTC Staining Kit enables the identification and analysis of diverse CTC phenotypes and clusters, providing valuable insights into cancer progression, metastasis, and treatment response.

What is the focus of ANGLE's commercial businesses?

ANGLE's commercial focus is on diagnostic products and clinical services, offering advanced liquid biopsy solutions and custom assay development for pharma.